School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
Angew Chem Int Ed Engl. 2022 Jul 11;61(28):e202203500. doi: 10.1002/anie.202203500. Epub 2022 May 20.
Selective activation of prodrugs is an important approach to reduce the side effects of disease treatment. We report a prodrug design concept for metal complexes, termed "metal-carrying prochelator", which can co-carry a metal ion and chelator within a single small-molecule compound and remain inert until it undergoes a specifically triggered intramolecular chelation to synthesize a bioactive metal complex in situ for targeted therapy. As a proof-of-concept, we designed a H O -responsive small-molecule prochelator, DPBD, based on the strong chelator diethyldithiocarbamate (DTC) and copper. DPBD can carry Cu (DPBD-Cu) and respond to elevated H O levels in tumor cells by releasing DTC, which rapidly chelates Cu from DPBD-Cu affording a DTC-copper complex with high cytotoxicity, realizing potent antitumor efficacy with low systemic toxicity. Thus, with its unique intramolecularly triggered activation mechanism, this concept based on a small-molecule metal-carrying prochelator can help in the prodrug design of metal complexes.
前药的选择性激活是减少疾病治疗副作用的一种重要方法。我们报告了一种金属配合物的前药设计概念,称为“载金属螯合剂”,它可以在单个小分子化合物中同时携带金属离子和螯合剂,并且在经历特定触发的分子内螯合之前保持惰性,以原位合成生物活性金属配合物用于靶向治疗。作为概念验证,我们基于强螯合剂二乙二硫代氨基甲酸盐 (DTC) 和铜设计了一种 H 2 O 2 响应的小分子前螯合剂 DPBD。DPBD 可以携带 Cu(DPBD-Cu),并通过释放 DTC 对肿瘤细胞中升高的 H 2 O 2 水平做出响应,DTC 从 DPBD-Cu 中迅速螯合 Cu,形成具有高细胞毒性的 DTC-铜配合物,实现了低全身毒性的强大抗肿瘤功效。因此,基于小分子载金属前螯合剂的这种独特的分子内触发激活机制,可以帮助设计金属配合物的前药。